在FIC EGFR ADC管线MRG003近期历经了一次申报波折，这仅稍稍拖慢了商业化步伐，不影响这款国内FIC大单品的获批终局；而MRG003更强的催化，也将在今年到来。

Copenhagen-based Adcendo is paying what is rumoured to be tens of millions of dollars in upfront fees for rights to Multitude's anti-tissue factor (TF) ADC AMT-754 – now renamed ADCE-T02 ...

CMG901是首个进入临床三期的Claudin18.2 ADC，全球进度最快;MRG004是进展最快的国产TF-ADC;HER2 ADC内卷之下，MRG002布局乳腺癌肝转移适应症，临床具备差异性 ...

While his AP TF is the more traditional way of playing the Card Master, many on-hit AD builds have also been taking over solo queue. Players have been flexing him as an ADC and a Top Laner to ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 10.88%, which has investors questioning if this is right time to buy.

At the front of its pipeline is ADCE-T02, a "highly differentiated" anti-tissue factor (TF) ADC that Adcendo licensed from Chinese biotech Multitude Therapeutics in the summer, in a deal with a ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

"Tissue factor (TF) is a validated ADC target with overexpression in many high unmet need solid tumor indications, however, the currently approved TF targeting ADC has severe limitations due to a ...

The study is currently recruiting in Australia and will start recruiting in the U.S. in the next few months. "Tissue factor (TF) is a validated ADC target with overexpression in many high unmet need ...